Baltimore Washington Financial Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Baltimore Washington Financial Advisors, Inc.

$1.8 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 03, 2020	SELL	$20.2 - $25.05 $414,140 - $513,575	-20,502 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$17.09 - $24.89 $10,681 - $15,556	-625 Reduced 2.96%	20,502 $486,000
Q1 2020 Apr 28, 2020	SELL	$14.45 - $24.69 $126,047 - $215,370	-8,723 Reduced 29.22%	21,127 $380,000
Q4 2019 Feb 04, 2020	SELL	$19.93 - $29.13 $182,817 - $267,209	-9,173 Reduced 23.51%	29,850 $708,000
Q3 2019 Oct 16, 2019	SELL	$25.47 - $33.37 $153,074 - $200,553	-6,010 Reduced 13.35%	39,023 $1.07 Million
Q2 2019 Jul 25, 2019	BUY	$29.96 - $38.87 $12,583 - $16,325	420 Added 0.94%	45,033 $1.49 Million
Q1 2019 Apr 18, 2019	BUY	$32.77 - $41.99 $225,260 - $288,639	6,874 Added 18.21%	44,613 $1.56 Million
Q4 2018 Jan 29, 2019	SELL	$30.84 - $49.51 $119,998 - $192,643	-3,891 Reduced 9.35%	37,739 $1.25 Million
Q3 2018 Nov 01, 2018	BUY	$42.7 - $56.55 $1.78 Million - $2.35 Million	41,630 New	41,630 $2.1 Million

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$376 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$221 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$184 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$104 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$95.1 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baltimore Washington Financial Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Baltimore Washington Financial Advisors, Inc. with notifications on news.

Account